Helix BioPharma Corp. has named Dr. Thomas Mehrling as its new Chief Executive Officer, signaling a strategic leadership transition designed to accelerate the company's oncology research and clinical development efforts. Dr. Mehrling, who previously served as Chief Medical Officer, brings over two decades of pharmaceutical oncology experience to the role.
With a distinguished background in hemato-oncology and pharmacology, Dr. Mehrling has a proven track record of developing transformative cancer therapies. His prior experience includes leadership positions at Mundipharma International Ltd., where he was instrumental in introducing cancer drugs that generated nearly USD 1 billion in sales.
The company plans to advance its lead candidate, L-DOS47, by entering a Phase II study in combination with pembrolizumab for non-small cell lung cancer treatment. This strategic move represents a significant milestone in Helix BioPharma's commitment to addressing challenging cancer treatments through innovative approaches.
Dr. Mehrling emphasized the company's focus on confronting urgent cancer challenges through smart innovation and rapid decision-making. The leadership transition comes as Helix prepares to secure financing to execute its clinical development strategy and expand its research team.
Outgoing CEO Jacek Antas will continue to serve as Chairman, supporting the company's growth and strategic objectives. The leadership change reflects Helix BioPharma's dedication to building a resilient and agile organization capable of delivering breakthrough oncology therapies.
